Bioavailability and swallowability of an age-appropriate, delayed-release mesalamine formulation in healthy volunteers

IF 3.1 Q2 PHARMACOLOGY & PHARMACY Clinical Pharmacology : Advances and Applications Pub Date : 2019-07-12 DOI:10.2147/CPAA.S193191
Abhijeet S. Jakate, B. Mcnamee, Donald Burkindine
{"title":"Bioavailability and swallowability of an age-appropriate, delayed-release mesalamine formulation in healthy volunteers","authors":"Abhijeet S. Jakate, B. Mcnamee, Donald Burkindine","doi":"10.2147/CPAA.S193191","DOIUrl":null,"url":null,"abstract":"Objective: Delayed-release mesalamine 400 mg capsules containing four 100 mg tablets have been developed for children with ulcerative colitis who have difficulty swallowing. Bioavailability of the mesalamine capsules was compared with existing mesalamine tablets in healthy adults, and the effect of food on bioavailability from mesalamine capsules was determined. Tablet swallowability in healthy children was evaluated. Methods: In the open-label, replicate-treatment, single-dose, crossover, comparative bioavailability study, healthy adult volunteers were randomized to one of four treatment sequences to receive mesalamine 400 mg tablets (fasted) twice, mesalamine 400 mg capsules (fasted) twice, and a mesalamine 400 mg capsule (with food) once, with ≥7 days between treatments. Pharmacokinetic (PK) parameters were calculated and analyzed using the reference-scaled average bioequivalence procedure. In the open-label, single-dose swallowability study, healthy children aged 5–11 years were asked to swallow eight placebo tablets identical to those contained in two mesalamine capsules. Results: In the bioavailability study (n=160), mesalamine capsules and tablets in fasted volunteers exhibited similarly delayed absorption and were shown to be bioequivalent; statistical parameters calculated from PK values met the criteria for bioequivalence. A slight increase in mesalamine bioavailability was observed with food administration, but the delayed-release performance of the capsules was not affected. Overall safety profiles between capsules and tablets were similar. In the swallowability study (n=60), the majority of children swallowed eight placebo tablets, with slight variability between age groups. Conclusion: Evaluation of PK parameters confirmed mesalamine capsules are bioequivalent to mesalamine tablets. Mesalamine capsules were well tolerated, can be administered with or without food, and are an age-appropriate product for children.","PeriodicalId":10406,"journal":{"name":"Clinical Pharmacology : Advances and Applications","volume":"11 1","pages":"93 - 101"},"PeriodicalIF":3.1000,"publicationDate":"2019-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/CPAA.S193191","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pharmacology : Advances and Applications","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/CPAA.S193191","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 3

Abstract

Objective: Delayed-release mesalamine 400 mg capsules containing four 100 mg tablets have been developed for children with ulcerative colitis who have difficulty swallowing. Bioavailability of the mesalamine capsules was compared with existing mesalamine tablets in healthy adults, and the effect of food on bioavailability from mesalamine capsules was determined. Tablet swallowability in healthy children was evaluated. Methods: In the open-label, replicate-treatment, single-dose, crossover, comparative bioavailability study, healthy adult volunteers were randomized to one of four treatment sequences to receive mesalamine 400 mg tablets (fasted) twice, mesalamine 400 mg capsules (fasted) twice, and a mesalamine 400 mg capsule (with food) once, with ≥7 days between treatments. Pharmacokinetic (PK) parameters were calculated and analyzed using the reference-scaled average bioequivalence procedure. In the open-label, single-dose swallowability study, healthy children aged 5–11 years were asked to swallow eight placebo tablets identical to those contained in two mesalamine capsules. Results: In the bioavailability study (n=160), mesalamine capsules and tablets in fasted volunteers exhibited similarly delayed absorption and were shown to be bioequivalent; statistical parameters calculated from PK values met the criteria for bioequivalence. A slight increase in mesalamine bioavailability was observed with food administration, but the delayed-release performance of the capsules was not affected. Overall safety profiles between capsules and tablets were similar. In the swallowability study (n=60), the majority of children swallowed eight placebo tablets, with slight variability between age groups. Conclusion: Evaluation of PK parameters confirmed mesalamine capsules are bioequivalent to mesalamine tablets. Mesalamine capsules were well tolerated, can be administered with or without food, and are an age-appropriate product for children.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
适合年龄的延迟释放美沙拉胺制剂在健康志愿者中的生物利用度和可吞性
目的:研制了400 mg美沙拉秦缓释胶囊,内含4片100 mg片剂,用于治疗吞咽困难的溃疡性结肠炎儿童。比较了美沙拉秦胶囊和现有美沙拉秦片在健康成年人中的生物利用度,并测定了食品对美沙拉秦片剂生物利用度的影响。对健康儿童的片剂可吞咽性进行了评估。方法:在开放标签、重复治疗、单剂量、交叉、比较生物利用度研究中,健康成年志愿者被随机分配到四个治疗序列中的一个,接受两次400 mg美沙拉秦片剂(禁食)、两次400毫克美沙拉秦胶囊(禁食)和一次400 mg美沙拉嗪胶囊(含食物),两次治疗间隔≥7天。使用参考比例平均生物等效性程序计算和分析药代动力学(PK)参数。在开放标签单剂量可吞咽性研究中,5-11岁的健康儿童被要求吞下八片安慰剂,与两粒美沙拉秦胶囊中的安慰剂相同。结果:在生物利用度研究中(n=160),禁食志愿者服用的美沙拉秦胶囊和片剂表现出类似的延迟吸收,并显示出生物等效性;根据PK值计算的统计参数符合生物等效性标准。在给药过程中,观察到美沙拉秦的生物利用度略有提高,但胶囊的延迟释放性能没有受到影响。胶囊和片剂的总体安全性相似。在吞咽能力研究(n=60)中,大多数儿童吞下了8片安慰剂,各年龄组之间略有差异。结论:PK参数评价证实美沙拉秦胶囊与美沙拉秦片具有生物等效性。美沙拉秦胶囊耐受性良好,可以与食物一起服用,也可以不与食物一起使用,是适合儿童年龄的产品。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.60
自引率
0.00%
发文量
14
审稿时长
16 weeks
期刊最新文献
Severe Hypertensive Response to Atropine Therapy for Bradycardia Associated with Dexmedetomidine: Case Report and Literature Review. Comparison of Efficacy and Safety Between Dronedarone and Amiodarone Used During the Blind Period in Patients with Atrial Fibrillation After Catheter Ablation Ipratropium Bromide/Salbutamol-Induced Acute Urinary Retention as a Result of Medication Error: A Case Report and Review of Cases in the Literature. Allopurinol-Induced Stevens-Johnson Syndrome (SJS). Systematic Review of Safety of RTS,S with AS01 and AS02 Adjuvant Systems Using Data from Randomized Controlled Trials in Infants, Children, and Adults.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1